Compare iShares MSCI South Korea ETF (EWY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI South Korea ETF trades at $178.33 (market cap $26.77B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: iShares MSCI South Korea ETF is far larger — about 11.6× Recursion Pharmaceuticals Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWY | RXRX | |
|---|---|---|
Market Cap | $26.77B | $2.31B |
Volume | 12,180,040 | 40,478,768 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $6.79 |
52-Week Low | $80.72 | $2.84 |
Typical Hold Time | 46 Days | 22 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) trades at $183.72, down 1.44% amid mixed technical signals with neutral overall momentum. The ETF faces pressure from rising oil prices and global bond yields impacting South Korean semiconductor stocks, though AI-driven demand provides underlying support. Recent volatility around the 7,000 KOSPI level reflects ongoing tension between technology sector strength and macroeconomic headwinds.
Outlook remains cautiously optimistic given South Korea's strong corporate earnings and AI infrastructure growth, but concentrated exposure to Samsung and SK hynix creates sensitivity to memory cycle fluctuations. Key risks include persistent inflation pressures and global semiconductor demand volatility that could challenge near-term performance despite long-term AI tailwinds.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
